CVT/Astellas Submit Next-Gen Cardiac Stress Agent Regadenoson
This article was originally published in PharmAsia News
Executive Summary
CV Therapeutics and Astellas Pharma submitted an NDA for their novel cardiac imaging stress agent regadenoson May 14, CVT told "The Pink Sheet" DAILY
You may also be interested in...
CVT/Astellas To Submit Regadenoson In Mid-2007, Following Successful Phase III Studies
Selective adenosine receptor agonist could replace market leader Adenoscan as the myocardial perfusion imaging agent of choice, CVT says.
CVT’s Ranexa Approved For Second-Line Angina
The partial fatty oxidation inhibitor will launch in late March.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).